Pioglitazone, a PPAR agonist, is also proposed as an effective treatment in COVID-19 people affected by type 2 diabetes, cardiovascular complications, and hypertension by reducing inflammatory parameters and also by inhibiting 3CLpro thereby downregulating SARS-CoV-2 RNA synthesis and replication (Carboni et al., 2020). This evidence concerns the gene PPARA and COVID-19.